Group 1 - The pharmaceutical industry in Jiangsu province is increasingly adopting a "go global" strategy, with banks like China Construction Bank (CCB) providing innovative financial services to support this initiative [1] - CCB Jiangsu branch is enhancing financial products and services to support the entire lifecycle of pharmaceutical companies, facilitating efficient cross-border transactions [1] - Eddy Pharmaceutical, a listed company focused on HIV drug development, is expanding into the African market while improving its domestic procurement processes through digital upgrades [2][3] Group 2 - CCB Yangzhou branch has formed a dedicated team to assist Eddy Pharmaceutical in optimizing its payment processes, leading to significant improvements in fund turnover efficiency [3] - In March 2025, Eddy Pharmaceutical successfully processed a payment of 10 million yuan through CCB's supply chain products, ensuring stable raw material supply and enhancing its reputation in the supply chain [3] - CCB Jiangsu branch has provided over 50 million yuan in credit support to Eddy Pharmaceutical, facilitating its international expansion efforts [3] Group 3 - Yuyue Group is actively expanding its international market presence, with CCB Zhenjiang branch providing substantial financial support, including a 3 billion yuan loan for acquisitions [4] - As of March 2025, CCB Zhenjiang branch has granted a total credit of 2.64 billion yuan to Yuyue Group, enabling the company to overcome barriers in overseas markets [4] - Yuyue Group's subsidiary, Juyue Medical, has secured a credit line of 60 million yuan from CCB Zhenjiang branch, further supporting its operational needs [4] Group 4 - CCB Lianyungang branch has been closely monitoring a well-known pharmaceutical group, assisting in resolving a cross-border RMB transaction that had been pending for nearly a year due to compliance issues [6][7] - The bank conducted a rapid compliance review and successfully processed the transaction within 48 hours, thereby maintaining the company's international business reputation [6][7] - This collaboration exemplifies CCB's commitment to supporting pharmaceutical companies in their international endeavors through effective cross-border RMB services [7]

Core Viewpoint - The article highlights the significant contributions of Huang Zhiwei, a returning scientist, in advancing basic research in life sciences at Harbin Institute of Technology, emphasizing the importance of foundational research for achieving high-level technological self-reliance and building a world-class scientific power [1][4]. Group 1: Research Achievements - Huang Zhiwei established a laboratory from scratch at Harbin Institute of Technology in 2012, focusing on basic research in immunology and infectious diseases [1]. - In 2014, his team discovered the structure of the HIV virus virulence factor, which had been elusive for over 30 years, providing a foundation for developing anti-HIV drugs [2]. - The research findings were published in the journal "Nature," attracting international attention and collaboration [2]. Group 2: Research Environment and Philosophy - Huang Zhiwei created a supportive research environment at the Life Sciences Center, allowing researchers to explore innovative ideas freely [3]. - He emphasizes the importance of hands-on involvement in experiments and meticulous record-keeping to ensure reproducibility and high-quality research outcomes [2][3]. - The center has produced significant breakthroughs in gene editing and metabolic disease mechanisms, establishing a competitive research platform internationally [3]. Group 3: Future Aspirations - Huang Zhiwei expresses a commitment to tackling unresolved scientific questions in life sciences, maintaining a beginner's mindset to explore frontiers and contribute to the field's advancement [4].